Admin « ACTC.OB investor blog

You're browsing posts from the
Blog Author

May 5, 2011
Posted by Admin

ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London

The company issued the following release today.
ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London
Mr. Rabin Will Discuss Two Upcoming Clinical Trials Using Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelial (RPE) Cells to Treat Macular Degeneration
MARLBOROUGH, Mass. — May 5, 2011 – Advanced Cell [...]

No Comments

Posted Under Uncategorized

May 2, 2011
Posted by Admin

Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research

The company issued the following press release today.
Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research
Ruling Could Provide Tremendous Boost to Regenerative Medicine Industry
MARLBOROUGH, Mass. — May 2, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today [...]

No Comments

Posted Under ACT Events Uncategorized

April 28, 2011
Posted by Admin

ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration

The company issued the following press release today.
UCLA’s Jules Stein Eye Institute to be a Site for Phase 1/2 Trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-related Macular Dystrophy (Dry AMD)
MARLBOROUGH, Mass. – April 28, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced [...]

No Comments

Posted Under Uncategorized

ACT's Company Blog.

Advanced Cell Technology, Inc. (OTCBB: ACTC) is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

You're browsing posts from the
Blog Author

ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London

Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research

ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration

ACTC.OB Stock Quote

Categories

Archives

Facebook

ACT Links

ACT's Company Blog.

Advanced Cell Technology, Inc. (OTCBB: ACTC) is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

You're browsing posts from theBlog Author

ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London

Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research

ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration

ACTC.OB Stock Quote

Categories

Archives

Facebook

ACT Links

You're browsing posts from the
Blog Author